Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults - A nationwide Registry-based study

European Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2010, Pages 619-625

  Gudbjornsson, Bjorn ^a,c   Thorsteinsson, Sigurdur B ^a   Sigvaldason, Helgi ^b   Einarsdottir, Rannveig ^a   Johannsson, Magnus ^a,c   Zoega, Helga ^b,c   Halldorsson, Matthias ^b   Thorgeirsson, Gudmundur ^a,c  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b Directorate of Health   (Iceland)

^c UNIVERSITY OF ICELAND   (Iceland)

Author keywords

COX 2 specific inhibitors; Nationwide; NSAID; Pharmacoepidemiology; Registry

Indexed keywords

CELECOXIB; DICLOFENAC; ETORICOXIB; IBUPROFEN; MISOPROSTOL; NAPROXEN; PARECOXIB; ROFECOXIB; VALDECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LACTONE; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONE;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; FEMALE; HEART INFARCTION; HUMAN; ICELAND; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; CHEMICALLY INDUCED DISORDER; FACTUAL DATABASE; INCIDENCE; REGISTER; RISK; RISK FACTOR; SUDDEN DEATH;

ANGINA, UNSTABLE; CEREBRAL INFARCTION; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DEATH, SUDDEN; FEMALE; HUMANS; ICELAND; INCIDENCE; LACTONES; MALE; MYOCARDIAL INFARCTION; ODDS RATIO; PYRAZOLES; REGISTRIES; RISK FACTORS; SULFONAMIDES; SULFONES; THROMBOEMBOLISM; YOUNG ADULT;

EID: 77954942943     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0789-2     Document Type: Article

References (31)

1. Rosen GD, Birkenmeier TM, Raz A, Holtzam MJ (1989) Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun 164:1358-1365
2. Raz A, Wyche A, Needleman P (1989) Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci USA 86:1657-1661
3. Han JW, Sadowski H, Young DA, Macara IG (1990) Persistent induction of cyclooxygenase in p60v-src-transformed 3T3 fibroblasts. Proc Natl Acad Sci USA 87:3373-3377
4. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235
5. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692-2696
6. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue. J Biol Chem 266:12866-12872
7. Simon LS, Lanza FL, Lipsky PE et al (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:1591-1602
8. Ehrich EW, Dallob A, De Lepeleire I et al (1999) Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 65:336-347
9. Baron JA, Sandler RS, Bresalier RS et al (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372:1756-1764
10. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080
11. Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884
12. Research Group ADAPT (2006) Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1 (7):e33
13. Aisen PS, Schafer KA, Grundman M et al (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819-2826
14. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021-2029
15. Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclooxygenase inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366-1372
16. Graham DJ, Campen D, Hui R et al (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475-481
17. Solomon DH, Schneeweiss S, Glynn RJ et al (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109:2068-2073
18. Fosbøl EL, Gislason GH, Jacobsen S et al (2009) Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 85:190-197
19. Statistics Iceland (2009) Population by sex and age. www.statice.is
20. Gebski V, Leung O, McNeil D, Lunn D (1992) Statistical package for interactive data analysis (SPIDA), version 6. Macquarie University, Sydney
21. Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH (2008) Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 168:1219-1224
22. Roumie CL, Mitchel EF Jr, Kaltenbach L, Arbogast PG, Gideon P, Griffin MR (2008) Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 39:2037-2045
23. Johnsen SP, Larsson H, Tarone RE et al (2005) Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165:978-984
24. Finckh A, Aronson MD (2005) Cardiovascular risks of cyclooxygenase- 2 inhibitors: where do we stand now? Ann Intern Med 142:157-164
25. Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA (2009) The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf 18:1016-1025
26. McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633-1644
27. Gislason GH, Jacobsen S, Rasmussen JN et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:2906-2913
28. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 68:367-372
29. Funk CD, FitzGerald GA (2007) COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 50:470-479
30. Bunimov N, Laneuville O (2008) Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets 8:268-277
31. Patrono C, Patrignani P, Garcia Rodriguez L (2001) Cyclooxygenaseselective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108:7-13